Gossamer Bio, Inc. balance sheet GOSS

Annual Quarterly

As of Jun 30, 2026, Gossamer Bio, Inc. had total assets of $76.9 million and total liabilities of $170.9 million. Total assets were down 68.1% from a year earlier. Stockholders' equity was negative, at -$94.0 million, because liabilities exceed assets. It held $57.0 million in cash and investments against $3.9 million of total debt, net cash of $53.1 million. The current ratio, current assets divided by current liabilities, was 0.53.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line	FY 2026 Jun 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019
Assets
Cash	41 +56.4%	38 -18.1%	46 +43.5%	32 -71.3%	112 -38.9%	183 -62.3%	486 +260.0%	135
Short-term investments	16 -91.5%	99 -60.1%	248 -6.0%	264 +83.9%	144 +1.3%	142 +433.7%	27 -90.0%	267
Long-term investments	0	0	—	—	—	—	—	—
Cash and investments	57 -73.2%	137 -53.5%	295 -0.6%	296 +15.9%	256 -21.4%	325 -36.6%	513 +27.6%	402
Receivables	6 -19.4%	12 +129.1%	5	—	—	—	—	—
Total current assets	73 -69.2%	168 -45.9%	310 +1.1%	307 +17.0%	262 -21.1%	332 -36.5%	522 +27.6%	409
Property and equipment, net	0 -27.6%	0 +540.0%	0 -99.4%	2 -58.6%	4 -25.2%	5 -3.9%	6 +2.0%	5
Total assets	77 -68.1%	172 -45.4%	315 +1.1%	312 +14.5%	272 -20.7%	344 -36.3%	539 +26.4%	427
Liabilities and equity
Accounts payable	6 +217.2%	6 +157.0%	2 -58.0%	6 +278.8%	1 -55.0%	3 -56.8%	8 +685.4%	1
Total current liabilities	138 +157.1%	63 +40.9%	45 -12.8%	52 +4.8%	49 +23.5%	40 +3.1%	39 +4.7%	37
Total liabilities	171 -40.5%	295 +3.2%	286 +14.7%	249 -4.3%	260 +17.2%	222 +1.6%	219 +195.1%	74
Stockholders' equity	-94 -103.9%	-123 -516.2%	29 -53.0%	63 +419.7%	12 -90.1%	121 -62.1%	321 -9.0%	352
Debt
Debt due within a year	—	—	—	12 +0.0%	12	—	—	—
Long-term debt	—	—	0 -100.0%	1 -93.2%	12 -58.8%	29 +1.2%	29 +1.0%	28
Lease liabilities	4 -18.7%	4 -17.9%	5 +55.5%	3 -46.4%	6 +5.0%	6 -46.1%	11 +2.3%	11
Total debt	4 -18.7%	4 -17.9%	5 -66.2%	16 -47.1%	30 -14.7%	35 -12.2%	40 +1.4%	40
Net cash	53 -74.5%	133 -54.2%	289 +3.1%	281 +24.3%	226 -22.2%	290 -38.6%	473 +30.5%	362
Ratios
Current ratio	0.53x	2.64x	6.88x	5.94x	5.32x	8.32x	13.51x	11.09x
Debt to equity	—	—	0.18x	0.25x	2.49x	0.29x	0.13x	0.11x
Return on equity	—	—	-191.67%	-286.47%	-1,899.30%	-192.65%	-75.89%	-51.15%
Return on assets	-162.91%	-98.91%	-17.93%	-57.65%	-84.19%	-68.09%	-45.11%	-42.27%
Book value per share	-0.19	-0.53	0.13	0.28	0.13	1.60	4.34	5.72

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: GOSS (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: San Diego, CA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1728117

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.